EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ANGPTL3, Apo CIII, Leptin and Triglycerides Are Elevated in Metastatic Prostate Cancer

Gabriel Boulay iD, Marwan Khodr, Ann-Charlotte Bergeron, Émilie Wong Chong iD, France-Hélène Joncas, Chloé Castonguay iD, Karine Robitaille iD, Hélène Hovington iD, Vincent Fradet iD, Alain Bergeron iD, Frédéric Pouliot iD, Jonatan Blais und 3 weitere

Cancers · 07.04.2026 · 18 (7) · 1176

DOI: 10.3390/cancers18071176 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 07.04.2026. Verfasst von Gabriel Boulay und 14 weiteren Autor:innen. Beteiligte Einrichtung: Faculté de Pharmacie, Université Laval, Québec City, QC G1V 0A6, Canada. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fonds de Recherche du Québec - Santé, CIHR, Fondation du CHU de Québec.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Prostate cancer (PCa) cells are known to heavily depend on lipids to support their growth. We hypothesized that hyperlipidemic factors, for which inhibitors are already available and used to treat cardiovascular disease, would be dysregulated in metastatic PCa (mPCa). The goal of this case-control study, including 35 men per group, was to compare the levels of PCSK9, ANGPTL3, Apo CIII, leptin, and the lipid profile in patients with mPCa versus localized Gleason 8/9 PCa (lPCa) and patients at risk of developing PCa (controls).

Methods

Protein levels were assessed using ELISAs, while lipids were measured using the Roche Cobas analytical platform.

Results

The following circulating analytes were higher in mPCa: triglycerides (in mmol/L; controls 1.7 ± 1.2, lPCa 1.5 ± 0.7, mPCa 2.3 ± 1.2, p = 0.0004), Apo CIII (in µg/mL; control 110.7 ± 55.7, lPCa 115.0 ± 57.64, mPCa 159.9 ± 96.7, p = 0.0179), ANGPTL3 (in ng/mL; controls 41.7 ± 20.0, lPCa 42.8 ± 24.1, mPCa 57.3 ± 26.9, p = 0.0390), and leptin (in ng/mL, controls 9.6 ± 9.1, lPCa 8.2 ± 7.9, mPCa 17.7 ± 17.8, p < 0.0001). Surprisingly, PCSK9 levels were negatively correlated with LDL in the entire cohort.

Conclusions

In this cohort of men, whole-body lipid metabolic rewiring is a feature restricted to the metastatic phase of prostate cancer, suggesting it may play a significant role in the progression toward more aggressive cancer forms. Given the availability of drugs targeting ANGPTL3 and Apo CIII, the therapeutic potential of these drugs should be evaluated in metastatic PCa.

Schlagwörter

Stichwörter der Autor:innen

ANGPTL3APOC3Lp(a)leptinlipid-lowering drugsmetastatic prostate cancertriglycerides

Autor:innen und Institutionen

  • Faculté de Pharmacie, Université Laval, Québec City, QC G1V 0A6, Canada.
  • Axe Oncologie, Centre de Recherche du CHU de Québec-Université Laval, Québec City, QC G1V 4G2, Canada.
  • Axe Neurosciences, Centre de Recherche du CHU de Québec-Université Laval, Québec City, QC G1V 4G2, Canada.
  • Faculté de Médecine, Université Laval, Québec City, QC G1V 0A6, Canada.
  • Centre de Recherche sur le Cancer (CRC)-Université Laval, Québec City, QC G1J 0J9, Canada.
  • Unité de Recherche en Biochimie Neuroendocrinienne, Institut de Recherches Cliniques de Montréal, Montréal, QC H2W 1R7, Canada.

ORCID-Profile: Gabriel Boulay, Émilie Wong Chong, Chloé Castonguay, Karine Robitaille, Hélène Hovington, Vincent Fradet, Alain Bergeron, Frédéric Pouliot, Nabil G Seidah, Frédéric Calon, Anne Gangloff

Förderung

  • Fonds de Recherche du Québec - Santé
  • CIHR
  • Fondation du CHU de Québec
  • Fonds de Recherche du Québec (FRQ)–Santé
  • Canadian Institutes of Health Research
  • CHU de Québec–Université Laval Research Centre
  • Canadian Cancer Research Society
  • Quebec Ministry of Economy

Zitieren

APA

Boulay, G., Khodr, M., Bergeron, A. C., Wong Chong, É., Joncas, F. H., Castonguay, C., Robitaille, K., Hovington, H., Fradet, V., Bergeron, A., Pouliot, F., Blais, J., Seidah, N. G., Calon, F., & Gangloff, A. (2026). ANGPTL3, Apo CIII, Leptin and Triglycerides Are Elevated in Metastatic Prostate Cancer. Cancers, 18(7), 1176. https://doi.org/10.3390/cancers18071176

Vancouver

Boulay G, Khodr M, Bergeron AC, Wong Chong É, Joncas FH, Castonguay C, et al. ANGPTL3, Apo CIII, Leptin and Triglycerides Are Elevated in Metastatic Prostate Cancer. Cancers. 2026;18(7):1176. doi:10.3390/cancers18071176

BibTeX
@article{Boulay2026,
  author = {Boulay, Gabriel and Khodr, Marwan and Bergeron, Ann-Charlotte and Wong Chong, Émilie and Joncas, France-Hélène and Castonguay, Chloé and Robitaille, Karine and Hovington, Hélène and Fradet, Vincent and Bergeron, Alain and Pouliot, Frédéric and Blais, Jonatan and Seidah, Nabil G and Calon, Frédéric and Gangloff, Anne},
  title = {ANGPTL3, Apo CIII, Leptin and Triglycerides Are Elevated in Metastatic Prostate Cancer},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {7},
  pages = {1176},
  doi = {10.3390/cancers18071176}
}
Kostenlos starten →